Elucidating genetic and epigenetic contributions to drug response variation is critical for the realization of personalized medicine, which may particularly benefit cancer patients, for whom anti-cancer agent-induced cytotoxicities are often major adverse reactions. Previous pharmacogenomic discoveries have utilized the HapMap lymphoblastoid cell line (LCL) model, on which the research community has accumulated extensive genotypic data and gene expression profiles. Given the complex nature of gene expression regulation, expanding the cell-based model to include epigenetic systems such as cytosine modifications has begun to allow novel pharmacoepigenetic studies that may enhance our understanding of drug response variation. Using a collection of the HapMap LCL samples, our team has profiled the genome-wide cytosine modification levels and explored the contribution of CpG modifications to anti-cancer agent-induced cytotoxicities. Specifically, in our recent pharmacogenomic study on clofarabine, we demonstrated that by integrating cytosine modifications, genetic variants, and gene expression phenotypes, we were able to significantly improve our ability to explain the phenotypic variance among individuals. Finally, advances in experimental techniques that can distinguish 5'-methylcytosine (5mC) and 5'-hydroxymethylcytosine (5hmC), the latter of which is a recently rediscovered nucleotide base in the human genome with potential unique biological functions, as well as stem cell technologies that can differentiate target tissues from induced pluripotent stem cells (iPSCs), will move forward the current pharmacoepigenetic and pharmacogenomic research to the next stage with higher molecular resolution and better clinical relevance.
Individual drug response is a likely complex trait that may be determined by both genetic and non-genetic factors (e.g., diet, life style). Pharmacogenetics aims to elucidate the genetic contribution to the variability of drug response among patients, by linking genetic variants, particularly single nucleotide polymorphisms (SNPs) and copy number variants (CNVs) to drug response phenotypes. For drugs with a narrow therapeutic index (i.e., those drugs with a narrow range of dose between efficacy and adverse reactions), pharmacogenetic studies may help identify patients who may respond well or suffer serious adverse reactions [1] . Since anti-cancer chemotherapies often cause serious adverse reactions in patients (e.g., neurotoxicity, cardiotoxicity, nephrotoxicity, and hepatotoxicity), being able to identify optimal patient groups by their genetic make-up could significantly enhance the care of cancer patients and their life quality by reducing and controlling unnecessary side effects.
RESEARCH HIGHLIGHT
With the technological advances in profiling SNP genotypes, pharmacogenomic studies have begun to allow genome-wide scans of the entire human genome for genetic variants responsible for drug response variation. Given the availability of extensive genotypic data from public resources, such as the 1000 Genomes Project [2] , as well as commercially available cell cultures, the International HapMap Project lymphoblastoid cell line (LCL) [3] samples have been widely used in pharmacogenomic studies [4] [5] . For example, using this cell-based model, significant progress has been made in pharmacogenomic discoveries for anticancer chemotherapies of various mechanisms, such as cisplatin (a platinating agent) [6] , etoposide (a topoisomerase inhibitor) [7] , and cytarabine (an antimetabolic agent) [8] , by leveraging the extensive genotypic and gene expression data available on these samples.
Gene expression, which is an intermediate and complex phenotype itself, underlies the variability of higher level cellular and whole-body phenotypes and traits (e.g., drug response, risks for complex diseases). The genetic architecture of gene expression has been investigated to demonstrate that cis-acting (local) SNPs may function as expression quantitative trait loci (eQTL) in humans, including using the model of HapMap CEU (Utah Residents with Northern and Western European ancestry) and YRI (Yoruba in Ibadan, Nigera) samples [9] . Besides genetic variants, epigenetic systems, which are heritable genomic features that do not change the DNA sequence, such as cytosine modifications (e.g., methylation of C at CpG dinucleotides), are known to play crucial roles in gene regulation, thus potentially implicating in determining variation in complex traits. To comprehensively understand the determinants of drug response, we therefore expanded the HapMap resources [1] by profiling genome-wide cytosine modification levels of >450000 CpG sites using the Illumina Infinium HumanMethylation450 BeadChip (450K array) in 133 HapMap CEU and YRI samples [10] , on which our group and collaborators have generated gene expression profiles using the Affymetrix Human Exon array [11] and drug response phenotypes on various anti-cancer agents. In addition, the availability of SNP genotypes on these samples has allowed us to investigate the genetic architecture of cytosine modifications and linked the modification quantitative trait loci (mQTL) to human complex traits [12] .
Of particular interest to us are the toxicities induced by anti-cancer agents, such as clofarabine. Clofarabine is a rationally designed, second-generation purine nucleoside antimetabolite for treating several hematologic malignancies including acute lymphoblastic leukaemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome [13] . Specifically, we performed epigenome-wide association study to detect CpG sites associated with the cytotoxicities induced by clofarabine in the HapMap CEU and YRI LCL samples [14] . We further integrated the pharmaoepigenetic results (i.e., CpGs associated with cytotoxicities) with results generated from two separate association studies: a genomewide association study (GWAS) on cytotoxicities using the HapMap SNP genotypic data; and an association analysis between cytotoxicities and gene expression phenotypes based on microarray. Six genes, SET binding protein 1 (SETBP1), BCL2-associated athanogene 3 (BAG3), kelch-like family member 6 (KLHL6), EH-domain containing 3 (EHD3), polypeptide N-acetylgalactosaminyltransferase 2 (GALNT2) and potassium voltage-gated channel, KQT-like subfamily, member 5 (KCNQ5) passed these three analyses [14] . siRNA knockdown of three top-ranking genes (SETBP1, BAG3, and KLHL6) in LCLs showed altered susceptibility to clofarabine-induced toxicities, thus confirming the functional relevance of these genes [14] . Therefore, by adding a pharmacoepigenetic arm (i.e., epigenome-wide association between modified cytosines and drug response), our pharmacogenomic discovery approach was effectively extended to integrate data across gene expression, cytosine modifications, and SNP genotypes. Interestingly, we demonstrated that by integrating CpG sites and SNPs, we could significantly enhance our understanding of drug response variation. An integrative model with three CpGs and three SNPs could explain 43.1% phenotypic variance (clofarabine-induced cytotoxicity). In contrast, a SNP-only model explained 29.8% of the variance, while a CpG-only model explained 34.8% of the variance [14] . This study demonstrated that by integrating epigenetic systems into pharmacogenomic research, we could significantly improve our understanding of the underlying mechanisms of drug response. Though this particular study was focused on integrating cytosine modifications in pharmacogenomics, integrating other epigenetic systems such as microRNAs and histone modifications would also enhance the current pharmacogenomic research [15] , given their crucial roles in regulating gene expression. However, the current epigenomic profiling technologies based on bisulfite conversion, such as the Illumina 450K array, cannot distinguish 5'-hydroxymethylcytosine (5hmC) from 5'-methylcytosine (5mC), the latter of which is the primary type of modified cytosines. Notably, previous studies have emerged to indicate that 5hmC is universal in the human genome as a stable molecular entity with a key role in transcriptional regulation universal [16] . In stem cells, mutations of Tet enzymes that catalyze the conversion of 5mC to 5hmC lead to specific phenotypes (e.g., myeloid malignancies), suggesting unique roles of 5hmC [17] . Recent advances in experimental techniques, e.g., the Tet-assisted Bisulfite Sequencing (TAB-Seq) [18] and Oxidative Bisulfite Sequencing (oxBS-Seq) [19] , are expected to help overcome this limitation of the current epigenomic profiling platforms and provide opportunities to better understand the epigenetic contributions to drug response phenotypes by determining the relative roles of different modified cytosines.
Although the LCL model has demonstrated its utility in pharmacogenomic discovery [4] , a fundamental problem of using this model is that the LCLs do not directly represent the tissues of toxicity (e.g., liver, kidney). Given the advances in stem cell technologies, it is now possible to make induced pluripotent stem cells (iPSCs) from adult cells [20] (e.g., the LCLs), which could further differentiate into other target tissues, thus allowing pharmacogenomic research on these iPSC-differentiated tissues. The prospect of exploring the epigenomic profiles during the differentiation pathway from iPSC will shed new light into the epigenetic mechanisms of cell differentiation, as well as allow exploration of the epigenetic contributions to drug response in target tissues differentiated from the LCL-derived iPSCs, which may be more clinically relevant. We expect that by combining novel stem cell technologies and epigenetic/epigenomic approaches, the current pharmacoepigenetic and pharmacogenomic research will be benefited to facilitate the realization of personalized medicine.
